Palivizumab for infection prevention in Inuit infants a review of the clinical effectiveness and cost-effectiveness
The purpose of this report is to determine the clinical effectiveness and cost effectiveness of universal versus high-risk palivizumab prophylaxis, and seasonal versus year-round palivizumab in Inuit children up to 4 years of age
Main Authors: | , |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
December 17, 2019, 2019
|
Edition: | Version 1.0 |
Series: | CADTH rapid response report: summary with critical appraisal
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references